Mind Medicine (MindMed) Inc. (OTCMKTS:MMEDF – Get Free Report)’s share price rose 3.9% during mid-day trading on Friday . The company traded as high as $46.18 and last traded at $46.14. Approximately 1,782,245 shares traded hands during trading, a decline of 47% from the average session volume of 3,376,665 shares. The stock had previously closed at $44.39.
Mind Medicine (MindMed) Stock Performance
The firm’s 50 day simple moving average is $37.45 and its 200-day simple moving average is $25.55.
About Mind Medicine (MindMed)
Mind Medicine (MindMed) is a clinical-stage biotechnology company focused on developing innovative therapies derived from psychedelic compounds to address mental health disorders and addiction. The company’s research pipeline includes programs based on LSD, psilocybin and 18-methoxycoronaridine (18-MC), targeting conditions such as anxiety disorders, attention-deficit/hyperactivity disorder (ADHD) and opioid dependence. MindMed seeks to build a portfolio of drug candidates that combine pharmacological efficacy with optimized dosing regimens and delivery methods.
Founded in 2019 and headquartered in New York City, MindMed operates research facilities in North America and Europe, collaborating with academic institutions and medical centers to advance its clinical trials.
Further Reading
- Five stocks we like better than Mind Medicine (MindMed)
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com's FREE daily email newsletter.
